Literature DB >> 28560232

The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond.

Mircea T Chiriac1, Mousumi Mahapatro1, Markus F Neurath1, Christoph Becker1.   

Abstract

It has become increasingly evident over the past two decades that the microbiota plays a nurturing role in the development of the immune system. This appears to be important since the amplitude of immune responses has a crucial regulatory function in homeostasis and the prevention of unwanted inflammation. Hence, a malfunctioning gut flora has been shown to play a key role in visceral medicine. Strong evidence demonstrates for example that intestinal inflammation can develop as a result of a dysregulated microbiota, deficient antimicrobial responses, and aberrant bacterial translocation into the bowel wall. In healthy individuals, the bacterial translocation is blocked by a single layer of highly specialized intestinal epithelial cells which forms a strong barrier that lines the gut wall. This structure is responsible for an efficient absorption of nutrients while keeping the luminal flora at bay. In susceptible individuals, for yet incompletely understood reasons, either defective epithelial barrier function or dysregulated microbial composition or microbial pathogens drive intestinal inflammation. Many therapeutic strategies focusing on the modulation of the microbiota have been proposed recently but future research including prospective human studies and gnotobiotic mouse models are still needed to evaluate the contribution and potential therapeutic value of individual bacteria to human health.

Entities:  

Keywords:  Animal colitis models; Fecal microbiota transplantation; Gut microbiota; Inflammatory bowel disease; Intestinal inflammation

Year:  2017        PMID: 28560232      PMCID: PMC5447169          DOI: 10.1159/000470892

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  104 in total

1.  A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility.

Authors:  Mahesh S Desai; Anna M Seekatz; Nicole M Koropatkin; Nobuhiko Kamada; Christina A Hickey; Mathis Wolter; Nicholas A Pudlo; Sho Kitamoto; Nicolas Terrapon; Arnaud Muller; Vincent B Young; Bernard Henrissat; Paul Wilmes; Thaddeus S Stappenbeck; Gabriel Núñez; Eric C Martens
Journal:  Cell       Date:  2016-11-17       Impact factor: 41.582

2.  Gut microbiota: married to our gut microbiota.

Authors:  Katrina Ray
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10       Impact factor: 46.802

3.  Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns.

Authors:  Maria G Dominguez-Bello; Elizabeth K Costello; Monica Contreras; Magda Magris; Glida Hidalgo; Noah Fierer; Rob Knight
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

4.  Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease.

Authors:  J O Lindsay; K Whelan; A J Stagg; P Gobin; H O Al-Hassi; N Rayment; M A Kamm; S C Knight; A Forbes
Journal:  Gut       Date:  2005-09-14       Impact factor: 23.059

5.  Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results.

Authors:  Bota Cui; Qiang Feng; Honggang Wang; Min Wang; Zhaoyuan Peng; Pan Li; Guangming Huang; Zheng Liu; Ping Wu; Zhining Fan; Guozhong Ji; Xin Wang; Kaichun Wu; Daiming Fan; Faming Zhang
Journal:  J Gastroenterol Hepatol       Date:  2015-01       Impact factor: 4.029

6.  Epithelial NEMO links innate immunity to chronic intestinal inflammation.

Authors:  Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis
Journal:  Nature       Date:  2007-03-14       Impact factor: 49.962

7.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

8.  Development of the human infant intestinal microbiota.

Authors:  Chana Palmer; Elisabeth M Bik; Daniel B DiGiulio; David A Relman; Patrick O Brown
Journal:  PLoS Biol       Date:  2007-06-26       Impact factor: 8.029

9.  Dominant fecal microbiota in newly diagnosed untreated inflammatory bowel disease patients.

Authors:  Lill Therese Thorkildsen; Felix Chinweije Nwosu; Ekaterina Avershina; Petr Ricanek; Gøri Perminow; Stephan Brackmann; Morten H Vatn; Knut Rudi
Journal:  Gastroenterol Res Pract       Date:  2013-11-17       Impact factor: 2.260

10.  Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation.

Authors:  Nicholas Arpaia; Clarissa Campbell; Xiying Fan; Stanislav Dikiy; Joris van der Veeken; Paul deRoos; Hui Liu; Justin R Cross; Klaus Pfeffer; Paul J Coffer; Alexander Y Rudensky
Journal:  Nature       Date:  2013-11-13       Impact factor: 49.962

View more
  3 in total

1.  Distinct systemic microbiome and microbial translocation are associated with plasma level of anti-CD4 autoantibody in HIV infection.

Authors:  Wanli Xu; Zhenwu Luo; Alexander V Alekseyenko; Lisa Martin; Zhuang Wan; Binhua Ling; Zhiqiang Qin; Sonya L Heath; Kendra Maas; Xiaomei Cong; Wei Jiang
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.996

2.  Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients.

Authors:  Lena M Biehl; Debora Garzetti; Fedja Farowski; Diana Ring; Martin B Koeppel; Holger Rohde; Philippe Schafhausen; Bärbel Stecher; Maria J G T Vehreschild
Journal:  PLoS One       Date:  2019-04-15       Impact factor: 3.240

Review 3.  Obesity: novel and unusual predisposing factors.

Authors:  Petra Hanson; Martin O Weickert; Thomas M Barber
Journal:  Ther Adv Endocrinol Metab       Date:  2020-05-19       Impact factor: 3.565

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.